Skeletal muscle is considered an important insulin-responsive endocrine organ, and decreased muscle mass contributes to impaired glycemic control and insulin resistance [30], which could contribute to the development of atherogenic dyslipidemia [31]. This evidence concerns the gene INS and metabolic syndrome.